Summit Therapeutics (SMMT) is down -27.4%, or -$5.88 to $15.58.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
- Summit Therapeutics: Buy/High Risk Rating Reiterated as Analyst Sees Attractive Upside to Unchanged $40 Target Despite HARMONi-3 Interim Miss
- Summit Therapeutics price target lowered to $31 from $32 at Clear Street
- Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)
- Summit Therapeutics options imply 7.3% move in share price post-earnings